Core Viewpoint - The company, 宜明昂科-B (01541), has seen a significant stock price increase following the announcement of its clinical trial applications for IMM2510, a treatment for immune-resistant non-small cell lung cancer (NSCLC) [1] Group 1: Clinical Trial Developments - The company has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510 for treating immune-resistant NSCLC [1] - Two additional Phase III registration clinical trials for different types of lung cancer have also been submitted recently [1] Group 2: Clinical Trial Results - Data from a Phase I study presented at the 2025 World Lung Cancer Conference showed that among 17 evaluable patients with advanced squamous NSCLC who had previously received immunotherapy, the objective response rate was 35.3% and the disease control rate was 76.5% [1] - The median duration of response was reported at 7.59 months, while the median progression-free survival was 9.4 months [1] Group 3: Future Plans - Based on the promising results, the company plans to further validate the efficacy and safety of IMM2510 through the upcoming Phase III clinical trials, aiming to provide more effective treatment options for lung cancer patients [1]
宜明昂科-B再涨超9% 公司近日提交IMM2510三期临床试验申请